BASILEA, Ceftobiprole – A Free Option?
![](/report_cover/5562/basilea_ceftobiprole_a_free_option_en.gif)
In continuation with our search for opportunities in “Drugs for Bad Bugs”, we reinstate our coverage on Basilea Pharma (BSLN), as it is trading close to cash value and offers a favorable risk reward profile. Upside could come from positive clinical data of Isavuconazole (BAL8577, PhIII, invasive fungal infections, partnered with Astellas), expected by YE12/1H13 and US approval of Toctino (2013). After entering into an exclusive worldwide agreement with Stiefel (GSK company) for Toctino (alitretinoin, L in major countries of ex-US; PhIII in US, Chronic Hand Eczema – CHE), BSLN now has teeth and cash buffer to attempt creating value from... For more detail, please read our initiation report released on 9th July, 2012 on BSLN titled “Ceftobiprole - A Free Option?
COMPANIES MENTIONED
Basilea
Basilea